相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer
Shannon N. Westin et al.
GYNECOLOGIC ONCOLOGY (2022)
XPO1 inhibition synergizes with PARP1 inhibition in small cell lung cancer by targeting nuclear transport of FOXO3a
Jingya Wang et al.
CANCER LETTERS (2021)
Antitumor efficacy of XPO1 inhibitor Selinexor in KRAS-mutant lung adenocarcinoma patient-derived xenografts
Joshua C. Rosen et al.
TRANSLATIONAL ONCOLOGY (2021)
FP14.08 Cabozantinib Plus Atezolizumab in NSCLC Patients Previously Treated with a Checkpoint Inhibitor: Results from COSMIC 021
J. Neal et al.
Journal of Thoracic Oncology (2021)
Phase Ib study to evaluate the safety of selinexor (SEL) in combination with pembrolizumab (PEM) in patients with advanced malignancies- the: The melanoma experience
I. C. Glitza et al.
ANNALS OF ONCOLOGY (2020)
Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migration
Asfar S. Azmi et al.
ONCOTARGET (2017)
XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer
Jimi Kim et al.
NATURE (2016)
KPT-330 has antitumour activity against non-small cell lung cancer
H. Sun et al.
BRITISH JOURNAL OF CANCER (2014)
Nuclear export of proteins and drug resistance in cancer
Joel G. Turner et al.
BIOCHEMICAL PHARMACOLOGY (2012)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Nuclear microenvironments in biological control and cancer
Sayyed K. Zaidi et al.
NATURE REVIEWS CANCER (2007)
Nuclear transport and cancer: From mechanism to intervention
TR Kau et al.
NATURE REVIEWS CANCER (2004)